Pharmaniaga tumbles 16% after wrapping up corporate exercises
PETALING JAYA : Pharmaniaga Bhd's shares fell 16% today even as it wrapped two key corporate proposals crucial to lifting the pharmaceutical group from its Practice Note 17 (PN17) classification.
Its shares fell 3.5 sen to close at its intra-day low of 18 sen, giving it a market capitalisation of RM883 million. It was the 11th most actively traded stock with 51.8 million shares changing hands.
The only major developments today were two bourse filings by the company providing further details on its rights issue and private placement proposals.
In May, Bursa Malaysia Securities granted Pharmaniaga a three-month extension to Aug 29 to implement its PN17 regularisation plan, which comprises a RM520 million capital reduction, a rights issue, and a private placement.
A massive impairment caused by its failure to offload RM552 million worth of Covid-19 vaccines sent Pharmaniaga tumbling into PN17 status in February 2023.
The impairment led to its largest ever quarterly net loss of RM664.39 million for Q4 FY2022.
A back-of-the-envelope calculation indicates the two corporate exercises raised a total of RM569.5 million, which will help to regularise the group's financial condition.
Pharmaniaga previously estimated total gross proceeds to be raised from the rights issue and private placement at a minimum of RM560.9 million to a maximum of RM641.4 million.
However, these exercises are also highly dilutive with about 5.1 billion new shares added to the share base. Today's announcements confirmed the new shares will be listed on July 31, which may explain the drop in the share price today.
Pharmaniaga previously unveiled a renounceable rights issue of up to 3.52 billion shares at 10 sen per share on the basis of 12 rights shares for every five existing shares.
Today's filing revealed 3.45 billion new shares were issued at the completion of the exercise, raising an estimated RM345.9 million.
The company also confirmed the placement to 'third-party investors' resulted in the issuance of 1.65 billion new shares at 13.5 sen per share, raising some RM223.6 million.
The placement shares were at a 6.6% discount based on the five-day volume-weighted average market price of Pharmaniaga shares of 14.46 sen as at June 16.
Today's announcement did not provide details on who the third-party investors were.
However, a recent report in The Edge weekly said textile wholesaler and retailer Jakel Group, Great Eastern, Koperasi Angkatan Tentera Malaysia Bhd, and shipping tycoon Halim Mohammad, were parties interested in taking up the placement shares, according to sources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
3 days ago
- New Straits Times
Pharmaniaga completes fundraising, edges closer to PN17 exit
KUALA LUMPUR: Pharmaniaga Bhd has made headway in its regularisation plan with the completion of its rights issue and private placement exercises, moving closer to exiting its Practice Note 17 (PN17) status. The pharmaceutical company said a total of 3.5 billion renounceable rights shares were fully subscribed, with an oversubscription rate of 26.14 per cent, indicating strong backing and confidence from existing shareholders. Additionally, the private placement exercise brought in 19 new investors and involved 1.6 billion shares, raising a total of RM223.7 million. "As both fundraising exercises have been completed, the group is set to conclude the final phase of its recovery plan, the capital reduction exercise which is targeted for completion by mid-August 2025. "This marks a major step forward in Pharmaniaga's recovery and efforts to exit PN17 status by the first quarter of 2026," it said. The group added that despite the fresh equity injection, Lembaga Tabung Angkatan Tentera and Boustead Holdings Bhd continue to be its major shareholders, collectively holding 43.9 per cent—comprising 8.7 per cent and 35.2 per cent stakes respectively. Pharmaniaga remains a government-linked company, maintaining its focus on national interests and the welfare of the Malaysian armed forces. Managing director Datuk Zulkifli Jafar said the oversubscription of the rights issue demonstrates strong market confidence in Pharmaniaga's business fundamentals, recovery strategy, and leadership. "The group also views the participation of the 19 new institutional and reputable investors in the private placement exercise as a clear endorsement, that aligns with our broader objective of contributing to Malaysia's healthcare resilience and pharmaceutical self-sufficiency, a shared national aspiration," he said. Zulkifli said the improved balance sheet allows the group to lower its debt and expand operations, particularly in high-impact areas like the development of human insulin, vaccines, and other generic medicines. "We are currently advancing the development of Malaysia's first locally owned insulin and vaccine production facilities," he added. Pharmaniaga's shares ended on a positive note, rising 9.38 per cent or 1.5 sen to close at 17.5 sen, with 218.5 million shares traded.
The Star
3 days ago
- The Star
Pharmaniaga completes private placement and rights issue; on track to exit PN17 by 1Q26
Pharmaniaga Bhd managing director Zulkifli Jafar. — AZLINA ABDULLAH/The Star PETALING JAYA: Pharmaniaga Bhd has completed a rights issue and a regularisation plan, allowing the company to remain on track to exit its PN17 status by the first quarter of 2026. In a statement, the company said a total of 3.46 billion renounceable rights shares were fully subscribed, with an oversubscription rate of 26.14%, reflecting strong support and confidence from existing shareholders. 'Meanwhile, the private placement exercise attracted 19 new investors, involving 1.66 billion placement shares at a total value of RM223.7mil.' Despite this new equity injection, Pharmaniaga said Lembaga Tabung Angkatan Tentera and Boustead Holdings Bhd remain the group's major shareholders at an aggregate shareholding of 43.9%, each holding 8.7% and 35.2% equity stake respectively. 'Pharmaniaga remains a government-linked company, with continued emphasis on national interest and the well-being of the Malaysian Armed Forces.' Pharmaniaga managing director Datuk Zulkifli Jafar said the oversubscription of the rights issue reflects 'deep market recognition of our business fundamentals, recovery plan and leadership.' 'The group also views the participation of the 19 new institutional and reputable investors in the private placement exercise as a clear endorsement, that aligns with our broader objective of contributing to Malaysia's healthcare resilience and pharmaceutical self-sufficiency, a shared national aspiration,' he said. As both fundraising exercises have been completed, the group is set to conclude the final phase of its regularisation plan, the capital reduction exercise which is targeted for completion by mid-August 2025. 'This marks a major step forward in Pharmaniaga's recovery and efforts to exit PN17 status by the first quarter of 2026,' said Zulkifli. He added that this strengthened balance sheet enables the group to reduce borrowings and scale up our operations, especially in high-impact areas such as development of human insulin, vaccines and other generic drugs. 'We are currently advancing the development of Malaysia's first locally owned insulin and vaccine production facilities.'
New Straits Times
3 days ago
- New Straits Times
Ireka shares surge 66pct, extending meteoric two-day rally
KUALA LUMPUR: Ireka Corp Bhd saw its share price soar by as much as 66 per cent during morning trade today, continuing its meteoric rally following a 63.89 per cent gain the previous day. The stock climbed 66 per cent to 30 sen during the morning session from its previous close of 18 sen. Yesterday, Bursa Malaysia issued an unusual market activity (UMA) query to the company in response to the sharp rise in both price and trading volume of Ireka shares on July 30, 2025. The market regulator has requested the company to disclose any material developments, rumours, or other factors that may explain the unusual trading activity. As of press time, Ireka has not responded to the query. Bursa said the company's response will be made available on its official website under the company announcements section once received. The surge in share price comes amid ongoing corporate developments involving a major infrastructure contract. On July 28, Ireka received a notice of mutual termination concerning its RM1.07 billion subcontract with Gammerlite Sdn Bhd for the Pan Borneo Highway project, following upstream funding constraints and the exit of the main contractor. The termination proposal was triggered by the lapse of a project operation agreement between main contractor MTD Construction Sdn Bhd and Sabah-based Gammerlite, which was terminated on June 30 due to Gammerlite's failure to secure the necessary funding. On July 8, Ireka received a mutual termination notice from Gammerlite. Ireka, however, objected to the termination and is currently seeking legal advice to evaluate avenues for cost recovery and fair compensation. "The company is pursuing an equitable settlement for work performed and costs incurred and anticipates legal and administrative expenses in connection with the dispute resolution process," Ireka said in a statement. The company officially entered Practice Note 17 (PN17) status on March 1, 2022, due to its shareholders' equity falling below 50 per cent of its share capital.
